Name

Carfilzomib

Alternate Names

Kyprolis

Abbreviations

None

Category

Chemotherapy

Subcategory

Proteasome inhibitor

NSC Number

None

Primary Site

Multiple myeloma

Histology

None

Remarks

September 4, 2020: FDA has approved Kyprolis (carfilzomib) and Darzalex (daratumumab) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

July 20, 2012 the FDA approved Kyprolis under the accelerated approval program for the treatment of multiple myeloma.

Coding

This drug should be coded
Glossary